Clinical Trials for Neurofibromatosis

Neurofibromatosis patient discussing clinical trials

Moffitt Cancer Center has a robust portfolio of clinical trials that offer unique treatment opportunities for patients who have been diagnosed with neurofibromatosis. This relatively uncommon genetic condition causes benign and sometimes malignant tumors to develop within the nervous system, including the brain, spinal cord and nerves. In some instances, even benign tumors can progress into malignant peripheral nerve sheath tumors.

Within the scientific community, all of the causes of neurofibromatosis are not yet fully understood. However, through extensive medical research studies, the team in Moffitt’s Neuro-Oncology Program is continually expanding the knowledge base about this complex condition, and our work is leading to better outcomes and quality of life for all current and future patients with neurofibromatosis.

What is a clinical trial and why should I consider participating?

A clinical trial is a research study that focuses on evaluating the effectiveness of a promising new treatment option as compared to the current standard of care. For instance, the aim of a neurofibromatosis clinical trial might be to assess the success of a new medication or a new combination of existing medications in stopping or slowing the growth of neurofibromas.

While many patients with neurofibromatosis are treated with surgery, chemotherapy, radiation therapy and/or targeted therapy, clinical trials present additional options that allow some patients to:

  • Access cutting-edge therapies that are not yet widely available in other settings
  • Take a more active role in their care
  • Contribute to important medical research that will help other patients with neurofibromatosis

Clinical trials are safe and the rights of the participants are well protected. Each study must first be approved by—and continually monitored by—an independent committee of physicians, scientists, community advocates and others.

Medical Reviewed by Dr. Peter Forsyth, Chair, Department of Neuro-Oncology  

If you have questions or would like to find neurofibromatosis clinical trials that are currently accepting new patients, please call 1-888-663-3488 or complete our new patient registration form online.

 

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 20487

Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease

Disease Site: Brain and Nervous System, Breast, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 20899

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Disease Site: Brain and Nervous System, Breast

View Trial Details

CLINICAL TRIAL 21022

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Disease Site: Any Site, Brain and Nervous System, Brain metastasis, Leptomeningeal (LMD), Lung, Pancreas, Rectum

View Trial Details

CLINICAL TRIAL 21039

A Pivotal Randomized, Open-Label Study Of OPTUNE(R)(TTFIELDS, 200KHZ) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma

Disease Site: Brain and Nervous System, Gliomas

View Trial Details

CLINICAL TRIAL 21193

Pre-operative Hypofractionated Stereotactic Radiosurgery for Resectable Brain Metastases

Disease Site: Brain and Nervous System, Brain metastasis

View Trial Details

CLINICAL TRIAL 21262

A First in Human dose escalation of Dendritic Cell Vaccine (DCV) administered Intrathecally (IT) primed against HER2/HER3 in Patients with Leptomeningeal Disease (LMD) from Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 21785

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 19731

CARING: Caregiver Assistance through Resources, Information, and Navigation Guide in Neuro-Oncology

Disease Site: Brain and Nervous System, Brain metastasis, Gliomas, Leptomeningeal (LMD), Meningiomas

View Trial Details

CLINICAL TRIAL 21737

A Pilot Study of Advanced Multi-parametric MRI to Evaluate De Novo Glioblastoma Tumors Prior to Surgical Resection

Disease Site: Brain and Nervous System, Gliomas

View Trial Details